With pegozafermin, 89bio could open up a new generation of treatment options where few effective therapies are currently available. The candidate is considered particularly promising for patients with moderate to severe MASH, as it has the potential to fundamentally change the standard of care.
For Roche, the integration of 89bio offers the opportunity to further expand its position in cardiovascular, renal and metabolic diseases and to leverage its own development and manufacturing network for accelerated market access. The acquisition is expected to be completed in 2025, until then 89bio will continue to operate independently.
Press release from "89bio, Inc. "dated 18 September 2025